Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dilated fundus examination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Dilated fundus examination. Displaying page 1 of 1.
    EudraCT Number: 2016-001119-19 Sponsor Protocol Number: A0661206 Start Date*: 2016-04-13
    Sponsor Name:Pfizer Inc.
    Full Title: Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/tonsillitis
    Medical condition: pharyngitis/tonsillitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10034835 Pharyngitis PT
    19.0 10021881 - Infections and infestations 10044008 Tonsillitis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004547-77 Sponsor Protocol Number: RN03-CP-0001 Start Date*: 2020-06-09
    Sponsor Name:ReNeuron Ltd
    Full Title: First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP)
    Medical condition: Retinitis Pigmentosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001179-21 Sponsor Protocol Number: 11-EI-0263 Start Date*: 2018-01-17
    Sponsor Name:The National Eye Institute
    Full Title: A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions
    Medical condition: Branch Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001143-12 Sponsor Protocol Number: 11-EI-0264 Start Date*: 2018-01-09
    Sponsor Name:The National Eye Institute
    Full Title: A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions
    Medical condition: Central Retinal Vein Occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-003253-36 Sponsor Protocol Number: LBS-008-CT03 Start Date*: Information not available in EudraCT
    Sponsor Name:Belite Bio, Inc
    Full Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
    Medical condition: Stargardt Disease
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000439-32 Sponsor Protocol Number: NW-3509/015/II/2019 Start Date*: 2021-04-28
    Sponsor Name:NEWRON PHARMACEUTICALS SPA
    Full Title: An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophre...
    Medical condition: Schizophrenia not responding adequately to current antipsychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10072913 Treatment-resistant schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001640-22 Sponsor Protocol Number: C-12-009 Start Date*: 2013-03-25
    Sponsor Name:Alcon Research Ltd
    Full Title: An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients
    Medical condition: Paediatric glaucoma
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-005056-15 Sponsor Protocol Number: AGO/2013/012 Start Date*: 2014-03-21
    Sponsor Name:UZ Gent
    Full Title: Longterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.
    Medical condition: Choroidal neovascularisation and chronic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10054467 Macular edema LLT
    21.1 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002696-10 Sponsor Protocol Number: CCPK850X2202 Start Date*: 2018-05-09
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa c...
    Medical condition: retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002395-75 Sponsor Protocol Number: NSR-REP-02 Start Date*: 2018-01-17
    Sponsor Name:NightstaRx Ltd (A Biogen Company)
    Full Title: An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
    Medical condition: Choroideremia (CHM)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10008791 Choroideremia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005192-18 Sponsor Protocol Number: A5351022 Start Date*: 2007-03-15
    Sponsor Name:Pfizer Ltd.
    Full Title: A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABET...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) SK (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003361-25 Sponsor Protocol Number: SHP640-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in...
    Medical condition: Bacterial Conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061784 Conjunctivitis bacterial PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) HU (Completed) ES (Completed) PL (Completed) AT (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002439-14 Sponsor Protocol Number: SHP640-301 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine...
    Medical condition: Adenoviral Conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10001257 Adenoviral conjunctivitis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) EE (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000437-41 Sponsor Protocol Number: NW-3509/014/II/2019 Start Date*: 2021-02-24
    Sponsor Name:NEWRON PHARMACEUTICALS SPA
    Full Title: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients...
    Medical condition: Schizophrenia not responding adequately to current antipsychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10072913 Treatment-resistant schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002248-95 Sponsor Protocol Number: BOFT-0418-SAFE Start Date*: 2018-09-26
    Sponsor Name:FAES FARMA S.A.
    Full Title: Multi-centre, randomised, double blind, placebo-controlled, parallel, phase III study to assess the safety, tolerability and efficacy of bilastine ophthalmic solution 0.6% in adults
    Medical condition: Allergic Conjunctivitis (AC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002098-86 Sponsor Protocol Number: BOFT-0520/PED Start Date*: Information not available in EudraCT
    Sponsor Name:FAES FARMA, S.A.
    Full Title: Multi-centre, randomised, double blind, placebo-controlled, parallel, phase III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution 0.6% in children
    Medical condition: Allergic conjunctivitis (AC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004844-35 Sponsor Protocol Number: TG-MV-005 Start Date*: 2009-07-01
    Sponsor Name:ThromboGenics NV
    Full Title: A randomized, sham-injection controlled, double-masked, multicenter trial of microplasmin intravitreal injection for treatment of exudative age-related macular degeneration (AMD).
    Medical condition: Patients with exudative AMD with focal vitreomacular adhesion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    9.1 10051065 Vitreomacular traction syndrome LLT
    9.1 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002942-12 Sponsor Protocol Number: P04737 Start Date*: 2007-10-22
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Dis...
    Medical condition: Documented coronary artery disease, postischemic cerebrovascular disease or peripheral artery disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043634 Thrombosis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) NL (Completed) SE (Completed) PT (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) AT (Completed) DE (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:38:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA